SCHEMBL13993536

SCHEMBL13993536

C[C@H]1CC[C@H](OCCN2CCOCC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.50
▸ MCHR1 Q99705 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ HRH3 Q9Y5N1 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ SCN1A P35498 1/20 0.37
▸ HTR2B P41595 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ SCN2A Q99250 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37
▸ SCN3A Q9NY46 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ SYK P43405 1/20 0.37
▸ LIPG Q9Y5X9 1/20 0.37
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8263002 1.00 NPC1 (0.50) NPC1MCHR1EPHX2HRH3ALDH1A1
SCHEMBL13086520 0.84 NPC1 (0.52) NPC1MCHR1EPHX2HRH3ALDH1A1
SCHEMBL18855748 0.84 NPC1 (0.71) NPC1MCHR1EPHX2ALDH1A1CYP1A2
SCHEMBL14654909 0.84 NPC1 (0.60) NPC1MCHR1HRH3ALDH1A1CYP1A2
SCHEMBL9703528 0.82 NPC1 (0.75) NPC1MCHR1EPHX2ALDH1A1CYP1A2
SCHEMBL13866421 0.82 NPC1 (0.46) NPC1MCHR1EPHX2HRH3ALDH1A1
SCHEMBL14652222 0.82 NPC1 (0.46) NPC1MCHR1EPHX2HRH3ALDH1A1
SCHEMBL14984925 0.82 NPC1 (0.46) NPC1MCHR1EPHX2HRH3ALDH1A1
SCHEMBL13798698 0.80 NPC1 (0.47) NPC1MCHR1EPHX2HRH3ALDH1A1
SCHEMBL79064 0.79 NPC1 (0.50) NPC1MCHR1EPHX2HRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791257-B2 Substituted pyrrolotriazines as protein kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-07-29 — — US disclosed
US-20130023514-A1 SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-24 — — US disclosed
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S ASTEX THERAPEUTICS LIMITED (UK) 2008-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S GSK3A, CDK11A, CDK1 NPC1 4170/4885MCHR1 2968/4885EPHX2 3157/4885
US-20130023514-A1 SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS STK25, MAP3K15, MAP3K5 NPC1 3239/4885MCHR1 3952/4885EPHX2 4340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback